

NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

Proposed Single Technology Appraisal

Canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein ID1362

Provisional Matrix of consultees and commentators

Consultees	Commentators (no right to submit or appeal)
<p><u>Company/sponsor</u></p> <ul style="list-style-type: none"> • Novartis (canakinumab) <p><u>Patient/carer groups</u></p> <ul style="list-style-type: none"> • Anticoagulation UK • Blood Pressure UK • Cardiac Risk in the Young • Cardiomyopathy UK • Cardiovascular Care Partnership • Circulation Foundation • Coronary Prevention Group • Different Strokes • HEART UK • Muslim Council of Britain • Network of Sikh Organisations • Pumping Marvellous • Somerville Foundation • South Asian Health Foundation • Specialised Healthcare Alliance • Stroke Association <p><u>Professional groups</u></p> <ul style="list-style-type: none"> • British Association for Nursing in Cardiovascular Care • British Association of Stroke Physicians • British Atherosclerosis Society • British Cardiovascular Intervention Society • British Cardiovascular Society • British Geriatrics Society • British Heart Foundation • British Hypertension Society • British Nuclear Cardiology Society • British Society for Haematology 	<p><u>General commentators</u></p> <ul style="list-style-type: none"> • All Wales Therapeutics and Toxicology Centre • Allied Health Professionals Federation • Board of Community Health Councils in Wales • British National Formulary • Care Quality Commission • Department of Health, Social Services and Public Safety for Northern Ireland • Healthcare Improvement Scotland • Medicines and Healthcare Products Regulatory Agency • National Association of Primary Care • National Pharmacy Association • NHS Alliance • NHS Confederation • Scottish Medicines Consortium • Welsh Health Specialised Services Committee <p><u>Comparators</u></p> <ul style="list-style-type: none"> • None <p><u>Relevant research groups</u></p> <ul style="list-style-type: none"> • British Society for Cardiovascular Research • Cardiac and Cardiology Research Dept, Barts • Cochrane Heart Group • Cochrane Hypertension Group • Cochrane Stroke Group • European Council for Cardiovascular Research • MRC Clinical Trials Unit

Provisional matrix for the proposed appraisal of canakinumab for preventing cardiovascular events after myocardial infarction in people with raised high-sensitivity C-reactive protein ID1362.

Issue date: March 2018. © National Institute for Health and Care Excellence 2018. All rights reserved.

<ul style="list-style-type: none"> • British Society for Haemostasis and Thrombosis • British Society for Heart Failure • British Society of Cardiovascular Imaging • British Society for Cardiovascular Research • British Thoracic Society • Clinical Leaders of Thrombosis • Royal College of Emergency Medicine • Royal College of General Practitioners • Royal College of Nursing • Royal College of Pathologists • Royal College of Physicians • Royal Pharmaceutical Society • Royal Society of Medicine • Society for Cardiological Science and Technology • Society for Vascular Nurses • Society for Vascular Technology • UK Clinical Pharmacy Association • UK Health Forum <p><u>Others</u></p> <ul style="list-style-type: none"> • Department for Health and Social Care • NHS England • NHS NHS Hull CCG • NHS South Manchester CCG • Welsh Government 	<ul style="list-style-type: none"> • National Centre for Cardiovascular Prevention and Outcomes • Heart Research UK • National Institute for Health Research • The Society for Research in Rehabilitation • Wellcome Trust <p><u>Associated Public Health Groups</u></p> <ul style="list-style-type: none"> • Public Health England • Public Health Wales
--	--

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the lists in the matrix, and which organisations we should include that have a particular focus on relevant equality issues.

PTO FOR DEFINITIONS OF CONSULTEES AND COMMENTATORS

Definitions:

Consultees

Organisations that accept an invitation to participate in the appraisal; the company that manufactures the technology; national professional organisations; national patient organisations; the Department of Health and the Welsh Government and relevant NHS organisations in England.

The company that manufactures the technology is invited to make an evidence submission, respond to consultations, nominate clinical specialists and has the right to appeal against the Final Appraisal Determination (FAD).

All non-company consultees are invited to submit a statement¹, respond to consultations, nominate clinical specialists or patient experts and have the right to appeal against the Final Appraisal Determination (FAD).

Commentators

Organisations that engage in the appraisal process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FAD for information only, without right of appeal. These organisations are: manufacturers of comparator technologies; Healthcare Improvement Scotland; other related research groups where appropriate (for example, the Medical Research Council [MRC], National Cancer Research Institute); other groups (for example, the NHS Confederation, NHS Alliance and NHS Commercial Medicines Unit, and the British National Formulary).

All non-company commentators are invited to nominate clinical specialists or patient experts.

¹Non-company consultees are invited to submit statements relevant to the group they are representing.